The global GLP-1 receptor agonist market size is valued at USD 53.5 billion in 2024 and is expected to grow to USD 62.86 billion by 2025. Looking ahead, the market is projected to reach approximately ...
Purpose: Patients undergoing axillary lymph node dissection (ALND) for breast cancer face a high risk of lymphedema, further increased by high body mass index (BMI) and insulin resistance. GLP-1 ...
GLP-1RA users did not have higher pancreatic cancer risk than basal insulin users. Pancreatic cancer risk is not associated with the use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) for up ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback